TheraRadar
← Back
Data updated: Jun 28, 2026

CHIESI FARMACEUTICI SPA

Biotech
RespiratoryDermatologyCardiovascular Execution: Good

CHIESI FARMACEUTICI SPA is a biotechnology company focused on Respiratory, Dermatology, Cardiovascular. Key products include MYALEPT.

2014
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

FDA Novel Drug Designations

(2023)
2 Novel 1 First-in-Class 1 Orphan 2 Priority Review 2 Fast Track
See 2 novel approvals →
2023 LAMZEDE (VELMANASE ALFA-TYCV) First-in-Class · Orphan · Priority Review · Fast Track
2023 ELFABRIO (PEGUNIGALSIDASE ALFA-IWXJ) Priority Review · Fast Track

CHIESI FARMACEUTICI SPA at a Glance

  • Fast trial execution (12 months median completion)

CHIESI FARMACEUTICI SPA's Key Drugs

CHIESI FARMACEUTICI SPA's core commercial portfolio centers on MYALEPT, LAMZEDE, ELFABRIO, spanning Respiratory and Dermatology — its most strategically important drugs approved in the last 15 years.

MYALEPT
Metabolic

Leptin Deficiency

Leptin Receptor Approved 2014
LAMZEDE
Rare Disease

Alpha-Mannosidosis

Alpha-mannosidase Approved 2023
ELFABRIO
Rare Disease

Fabry Disease

alpha-galactosidase A Approved 2023

CHIESI FARMACEUTICI SPA's Recent FDA Approvals

New NDA/BLA approvals for CHIESI FARMACEUTICI SPA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CHIESI FARMACEUTICI SPA's Therapeutic Areas

CHIESI FARMACEUTICI SPA's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Dermatology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 95%
0 drugs Phase 3: 32 Phase 2: 39 Phase 1: 39
Dermatology 2%
0 drugs Phase 3: 1
Cardiovascular 2%
0 drugs Phase 3: 1
Neurology 2%
0 drugs Phase 2: 2
Gastroenterology 0%
0 drugs Phase 1: 1

CHIESI FARMACEUTICI SPA's Top Competitors

CHIESI FARMACEUTICI SPA's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, CHIESI, and MALLINCKRODT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

APOTHECON specialty
Dermatology, Cardiovascular, Gastroenterology, Respiratory
CHIESI big-pharma
Respiratory, Cardiovascular, Dermatology, Neurology, Gastroenterology
MALLINCKRODT specialty
Respiratory, Gastroenterology, Cardiovascular, Dermatology
Bayer big-pharma
Cardiovascular, Respiratory, Dermatology
BAUSCH specialty
Dermatology, Cardiovascular, Gastroenterology

CHIESI FARMACEUTICI SPA Pipeline Snapshot

CHIESI FARMACEUTICI SPA has 115 active clinical programs from ClinicalTrials.gov — 34 Phase 3, 41 Phase 2 and 40 Phase 1.

34
Phase 3
41
Phase 2
40
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MYALEPT leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 31/44 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges